Peter Blurton

Title: The Innovative Contributions of Peter Blurton

Introduction

Peter Blurton is a notable inventor based in Welwyn Garden City, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit gastric acid secretion. With a total of 3 patents to his name, Blurton's work has had a meaningful impact on medical science.

Latest Patents

Among his latest patents, one includes "Pyrrolocinnolines for use as inhibitors of gastric acid secretion." This invention focuses on a compound known as 1-(2-methylphenyl)-2,3-dihydropyrrolo-[3,2-c]-cinnoline, which serves as an effective inhibitor of gastric acid secretion. Another significant patent is "Intermediates for 3-amino-1,2,5-thiadiazole-1-oxides." This invention relates to intermediates of Mannich-alkynyl aminothiadiazole oxides that exhibit histamine H₂-antagonist activity, with a particular final product being 3-amino-4-[7-piperidinohept-5-ynylamino]-1,2,5-thiadiazole-1-oxide.

Career Highlights

Peter Blurton is currently associated with Smith Kline & French Laboratories Limited, where he continues to innovate and develop new pharmaceutical solutions. His work has been instrumental in advancing the understanding and treatment of various medical conditions.

Collaborations

Blurton has collaborated with several professionals in his field, including his coworker Thomas H Brown. These collaborations have further enhanced the quality and impact of his inventions.

Conclusion

Peter Blurton's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work continues to influence the development of effective treatments for gastric acid-related conditions.